Last reviewed · How we verify
mRNA-1273 Variant-containing Formulation
mRNA-1273 Variant-containing Formulation is a mRNA vaccine Biologic drug developed by ModernaTX, Inc.. It is currently FDA-approved for COVID-19 prevention (variant-containing booster formulation).
mRNA-1273 Variant-containing Formulation encodes instructions for cells to produce spike proteins from SARS-CoV-2 variants, triggering an immune response against those variants.
mRNA-1273 is ModernaTX's marketed mRNA vaccine targeting COVID-19 prevention in adults 18+. The vaccine leverages Moderna's proprietary mRNA platform to encode the SARS-CoV-2 spike protein, enabling rapid immune response generation. This variant-containing formulation represents an evolution of the original vaccine, designed to address emerging viral variants and maintain clinical efficacy. With 4 clinical trials supporting its development and significant commercial deployment, mRNA-1273 demonstrates the viability of mRNA technology for infectious disease prevention. The vaccine's success has established mRNA as a validated modality and positioned Moderna as a leader in next-generation vaccine development.
At a glance
| Generic name | mRNA-1273 Variant-containing Formulation |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein (variant-specific) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This is an updated mRNA vaccine formulation that contains genetic instructions for producing spike proteins from circulating SARS-CoV-2 variants (such as Omicron subvariants). When administered, the mRNA is taken up by cells, translated into variant spike proteins, and presented to the immune system to generate antibodies and T-cell responses against those specific variants. This approach aims to provide improved protection against evolving viral strains.
Approved indications
- COVID-19 prevention (variant-containing booster formulation)
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Fever
- Chills
Key clinical trials
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 (PHASE4)
- A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) (PHASE4)
- COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA-1273 Variant-containing Formulation CI brief — competitive landscape report
- mRNA-1273 Variant-containing Formulation updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI
Frequently asked questions about mRNA-1273 Variant-containing Formulation
What is mRNA-1273 Variant-containing Formulation?
How does mRNA-1273 Variant-containing Formulation work?
What is mRNA-1273 Variant-containing Formulation used for?
Who makes mRNA-1273 Variant-containing Formulation?
What drug class is mRNA-1273 Variant-containing Formulation in?
What development phase is mRNA-1273 Variant-containing Formulation in?
What are the side effects of mRNA-1273 Variant-containing Formulation?
What does mRNA-1273 Variant-containing Formulation target?
Related
- Drug class: All mRNA vaccine drugs
- Target: All drugs targeting SARS-CoV-2 spike protein (variant-specific)
- Manufacturer: ModernaTX, Inc. — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for COVID-19 prevention (variant-containing booster formulation)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing